Laura Hulea

Laura Hulea is an Accredited Professor affiliated with the Maisonneuve-Rosemont Hospital Research Center at the University of Montreal. Her research focuses on cancer metabolism, cellular energetics, and the role of signaling pathways like mTOR in oncogenesis and therapy resistance. Her work intersects biochemistry, molecular biology, and translational medicine, with applications in drug development for cancers such as multiple myeloma and acute myeloid leukemia. She investigates metabolic vulnerabilities in cancer cells and explores repurposing antidiabetic drugs like canagliflozin for oncology.

Her studies span topics including mitochondrial function, protein synthesis regulation, and epigenetic modifications influencing tumor growth. Notably, her team examines how metabolic perturbations induced by environmental stressors or pharmacological agents can be exploited for therapeutic benefit. Recent work highlights the interplay between oncogenic kinases, translational control, and metabolic plasticity.

Laura Hulea’s research emphasizes cross-disciplinary approaches to dissect how cellular metabolism and signaling pathways drive cancer progression. She has contributed to understanding how mTOR signaling impacts aging, lifespan, and mitochondrial dynamics, with implications for both cancer and age-related diseases. Her publications reflect a focus on translational research, aiming to bridge basic science and clinical applications.